A double-masked, placebo-controlled study of fluoxetine for hypochondriasis / Brian A. Fallon en Journal of Clinical Psychopharmacology, Año 2008 - Vol. 28 - No. 6 (Diciembre)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2008 - Vol. 28 - No. 6 (Diciembre) . - pp. 638-645 Título : A double-masked, placebo-controlled study of fluoxetine for hypochondriasis Tipo de documento: texto impreso Autores: Brian A. Fallon, Autor ; Eva Petkova, Autor ; Natalia Skritskaya, Autor Fecha de publicación: 2023 Artículo en la página: pp. 638-645 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Envejecimiento, Connecticut, Fluoxetina - efectos adversos, Hipocondría - psicología, Abandonos de pacientes, Inhibidores selectivos de la recaptación de serotonina. Resumen: This study assessed the efficacy, durability, and tolerability of fluoxetine for hypochondriasis, a disorder for which controlled pharmacological trials are scarce. Fifty-seven patients with hypochondriasis were enrolled: 12 discontinued during the placebo run-in, and 45 were randomized to either fluoxetine or placebo for 12 weeks (acute treatment). Responder status was defined as a Clinical Global Impression rating for hypochondriasis of much or very much improved. Link: ./index.php?lvl=notice_display&id=30822 [artículo] A double-masked, placebo-controlled study of fluoxetine for hypochondriasis [texto impreso] / Brian A. Fallon, Autor ; Eva Petkova, Autor ; Natalia Skritskaya, Autor . - 2023 . - pp. 638-645. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2008 - Vol. 28 - No. 6 (Diciembre) . - pp. 638-645 Palabras clave: Envejecimiento, Connecticut, Fluoxetina - efectos adversos, Hipocondría - psicología, Abandonos de pacientes, Inhibidores selectivos de la recaptación de serotonina. Resumen: This study assessed the efficacy, durability, and tolerability of fluoxetine for hypochondriasis, a disorder for which controlled pharmacological trials are scarce. Fifty-seven patients with hypochondriasis were enrolled: 12 discontinued during the placebo run-in, and 45 were randomized to either fluoxetine or placebo for 12 weeks (acute treatment). Responder status was defined as a Clinical Global Impression rating for hypochondriasis of much or very much improved. Link: ./index.php?lvl=notice_display&id=30822

---

1 (1 - 1 / 1)